These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1652 related items for PubMed ID: 26294090

  • 1. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G.
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.
    Garcia-Manero G.
    Am J Hematol; 2011 Jun; 86(6):490-8. PubMed ID: 21594886
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Myelodysplastic syndromes: Contemporary review and how we treat.
    Gangat N, Patnaik MM, Tefferi A.
    Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
    [Abstract] [Full Text] [Related]

  • 9. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
    Stone R, Sekeres M, Garcia-Manero G, Lyons RM.
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003
    [Abstract] [Full Text] [Related]

  • 10. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
    Itzykson R, Fenaux P.
    Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Myelodysplastic syndromes].
    Thol F, Heuser M, Ganser A.
    Internist (Berl); 2015 Apr; 56(4):364-73. PubMed ID: 25700647
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
    Aul C, Giagounidis A, Germing U, Ganser A.
    Med Klin (Munich); 2002 Nov 15; 97(11):666-76. PubMed ID: 12434275
    [Abstract] [Full Text] [Related]

  • 17. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M, Zeidan AM.
    Cancer; 2017 May 15; 123(10):1703-1713. PubMed ID: 28192601
    [Abstract] [Full Text] [Related]

  • 18. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U, Schroeder T, Kaivers J, Kündgen A, Kobbe G, Gattermann N.
    Expert Rev Hematol; 2019 Oct 15; 12(10):893-908. PubMed ID: 31353975
    [Abstract] [Full Text] [Related]

  • 19. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
    Falantes JF, Calderón C, Márquez Malaver FJ, Alonso D, Martín Noya A, Carrillo E, Martino ML, Montero I, González J, Parody R, Espigado I, Pérez-Simón JA.
    Clin Lymphoma Myeloma Leuk; 2013 Apr 15; 13(2):144-52. PubMed ID: 23137720
    [Abstract] [Full Text] [Related]

  • 20. Evolving treatment options of myelodysplastic syndromes.
    Verbeek W, Ganser A.
    Ann Hematol; 2001 Sep 15; 80(9):499-509. PubMed ID: 11669297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 83.